Yarrow Bioscience (YARW) Depreciation & Amortization (CF) (2019 - 2026)
Yarrow Bioscience's (YARW) quarterly Depreciation & Amortization (CF) came in at $6000.0 in Q1 2026, little changed YoY from $6000.0 in Q1 2025, and little changed on a QoQ basis from $6000.0 in Q2 2025.
Yarrow Bioscience (YARW) Depreciation & Amortization (CF) (2019 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 6 years of Depreciation & Amortization (CF) data on file, last reported at $6000.0 in Q1 2026.
- Quarterly Depreciation & Amortization (CF) changed 0.0% year-over-year to $6000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $18000.0 (up 200.0% YoY) and the FY2025 annual result came in at $23000.0, up 475.0% from the prior year.
- Depreciation & Amortization (CF) was little changed at $6000.0 in Q1 2026, from $6000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $171000.0 in Q3 2022 to a low of -$155000.0 in Q4 2022.
- A 3-year average of $12857.1 and a median of $6000.0 in 2025 frame the typical range for Depreciation & Amortization (CF).
- The widest YoY moves for Depreciation & Amortization (CF): up 510.71% in 2022, down 696.15% in 2022.
- Tracing YARW's Depreciation & Amortization (CF) over 3 years: stood at -$155000.0 in 2022, then soared by 103.87% to $6000.0 in 2025, then changed by 0.0% to $6000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $6000.0 (Q1 2026), $6000.0 (Q2 2025), and $6000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | 6,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6,000.00 |
| Jun 30, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Mar 31, 2026 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Mar 31, 2025 | 6,000.00 |
| Dec 31, 2022 | -155,000.00 |
| Dec 31, 2022 | -155,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Sep 30, 2022 | 171,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Jun 30, 2022 | 12,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Mar 31, 2022 | 44,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Dec 31, 2021 | 26,000.00 |
| Sep 30, 2021 | 28,000.00 |
| Sep 30, 2021 | 28,000.00 |